We have located links that may give you full text access.
A close positive correlation between malodor and sweating as a marker for the treatment of axillary bromhidrosis with Botulinum toxin A.
Journal of Dermatological Treatment 2012 December
BACKGROUND: Botulinum toxin A (BTX-A) has been demonstrated to be only effective for some types of axillary bromhidrosis. It is necessary to explore the indications for BTX-A application.
METHODS: Sixty-seven consecutive outpatients with axillary bromhidrosis were recruited after informed content. Then, 50 U of BTX-A was injected intracutaneously into 20 different sites within each axilla. The follow-up was done every month and terminated when the malodor returned to the previous level.
RESULTS: Of 67 cases, 74.6% (50/67) had mild or moderate malodor, and 80.6% (54/67) experienced mild or moderate sweating. In 76.1% (51/67) of patients, there were a close correlation between malodor and sweating. After BTX-A injection, the malodor was eliminated in 73.1% (49/67) of patients. Logistic regression analysis revealed that the correlation between malodor and sweating differed significantly between the group that maintained no malodor after initial injection and the group that still exhibited malodor.
CONCLUSION: BTX-A ameliorates malodor mainly by the inhibition of eccrine and apoeccrine sweating but no apocrine sweating. A close positive correlation between malodor and sweating is the indication for BTX-A treatment.
METHODS: Sixty-seven consecutive outpatients with axillary bromhidrosis were recruited after informed content. Then, 50 U of BTX-A was injected intracutaneously into 20 different sites within each axilla. The follow-up was done every month and terminated when the malodor returned to the previous level.
RESULTS: Of 67 cases, 74.6% (50/67) had mild or moderate malodor, and 80.6% (54/67) experienced mild or moderate sweating. In 76.1% (51/67) of patients, there were a close correlation between malodor and sweating. After BTX-A injection, the malodor was eliminated in 73.1% (49/67) of patients. Logistic regression analysis revealed that the correlation between malodor and sweating differed significantly between the group that maintained no malodor after initial injection and the group that still exhibited malodor.
CONCLUSION: BTX-A ameliorates malodor mainly by the inhibition of eccrine and apoeccrine sweating but no apocrine sweating. A close positive correlation between malodor and sweating is the indication for BTX-A treatment.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app